CD, It might be helpful to all involved to know again how we define "on topic". Does a material development regarding another drug that may impact the market opportunity, and therefore the calculations of potential SP meet the hurdle? Would a comment about a politician's position on the market, another potential / comparable treatment, or an agency having influence on our opportunity as investors fit? Lots of gray area. I am asking sincerely, because I don't understand the fence line very well.

BTW, I appreciate the commitment made by any and all mods who are trying to guide the discussion for best benefit. Thank you!